hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-14. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Jon Wiederhorn of Rolling Stone called the album "liberating and enlightening, the songs achieve a startling, staggering and palpable impact." The band released the home video The Nona Tapes On December 12, a mockumentary featuring interviews with the band members conducted by journalist Nona Weisbaum (played by Jerry Cantrell), and the music video for "Grind". The band opted not to tour in support of Alice in Chains, adding to the rumors of drug abuse. The song "Got Me Wrong" unexpectedly charted three years after its release on the Sap EP. The song was re-released as a single on the soundtrack for the film Clerks in 1994, reaching number seven on the Mainstream Rock Tracks chart. Alice in Chains resurfaced on April 10, 1996, to perform for MTV Unplugged, a program featuring all-acoustic set lists. The performance featured some of the band's highest-charting singles, including "Rooster", "Down in a Hole", "Heaven Beside You", "No Excuses" and "Would?", and introduced a new song, "Killer Is Me", with Cantrell on lead vocals. The show marked Alice in Chains' only appearance as a five-piece band, adding second guitarist Scott Olson. A live album of the performance was released in July 1996, which debuted at number three on the Billboard 200, and was accompanied by a home video release, both of which received platinum certification by the RIAA. The band also appeared on The Late Show with David Letterman on May 10, 1996, performing the songs "Again" and "We Die Young".
Tempeh originated in Indonesia. According to historical evidence, tempeh was first made in Bayat, Klaten, Central Java, and was commonly consumed around 1700. The invention of tempeh seems to have arisen through the serendipitous introduction to stored soybeans of the fungus, which is crucial in tempeh's fermentation. This fungus grows on teakwood and sea hibiscus leaves, which native Javanese people often used (and still do) as food wrappings. In fact, in traditional tempeh making, an usar (a mycelium-filled leaf) is used, instead of store-bought ragi. The type of soybean first used to make tempeh was the black soybean, which was a native plant. This later changed with the importation of white or yellow soybeans and the rise of the tofu industry on the island. While tempeh has not been prominent far from its region of origin, it was reported to have "suddenly taken off" in the United Kingdom in 2025, with annual sales of one brand increasing by 736% (and another by 128%). In North America, a compound growth rate of 6.1% is expected in the tempeh market from 2024-2030, reaching $1519.8 million by 2030.
hoasca or oasca in Brazil yagé (or yajé, from the Cofán language or iagê in Portuguese). Relatively widespread use in Andean and Amazonian regions throughout the border areas of Colombia, Peru, Ecuador and Brazil. The Cofán people also use the word oofa. caapi (or kahpi/gahpi in Tupi–Guarani language or *kaapi in proto-Arawak language), used to address both the brew and the B. caapi itself. Meaning "weed" or "thin leaf", it was the word utilized by Spruce for naming the liana. pinde (or pindê/pilde), used by the Colorado people patem (or nátema), from the Chicham languages shori, mii (or miiyagi) and uni, from the Yaminawa language nishi cobin, from the Shipibo language nixi pae, shuri, ondi, rambi and rame, from the Kashinawa language kaji, kadana and kadanapira, used by the Tucano people kamarampi (or kamalampi) and hananeroca, from the Arawakan languages bakko, from Bora-Muinane languages jono pase, used by Ese'Ejja people uipa, from Guahibo language napa (or nepe/nepi), used by Tsáchila people Biaxije, from Kamëntšá language Cipó ("liana") or Vegetal, in Portuguese language, used by União do Vegetal church members Daime or Santo Daime, meaning "give me" in Portuguese, the term was coined by Santo Daime's founder Mestre Irineu in the 1940s, from a prayer dai-me alegria, dai-me resistência ("give me happiness, give me strength").
=== As a dietary supplement === Montmorency cherry juice is produced as a dietary supplement, and is manufactured as a concentrate and in capsules as a freeze-dried powder. Claims have been made that cherry juice can be helpful for improving sleep for people with insomnia, but there is no good evidence to support these claims.
Sources: en.wikipedia.org
=== Murder of Catherine "Rena" West === Rena maintained sporadic contact with her children on each occasion she and Fred separated. She is also known to have visited Fred's family in Much Marcle, Herefordshire, to enquire as to her children's whereabouts and welfare in the latter half of August 1971. Fred's sister-in-law, Christine, later recollected Rena was depressed and extremely anxious about her children. Being provided with Fred's Midland Road address, Rena sought to confront him—likely to discuss or demand custody of her daughters. This was the last time Rena was seen alive. She is believed to have been murdered by strangulation, possibly in the back seat of Fred's Ford Popular and likely while intoxicated. When Rena's body was discovered, a short length of metal tubing was found with her remains, leaving open a possibility she had been restrained and subjected to a sexual assault prior to her murder. The body was extensively dismembered, placed into plastic bags and buried close to a cluster of trees, known as Yewtree Coppice, at Letterbox Field.
=== Types of toxicity === Acute toxicity occurs over hours or a few days. Chronic toxicity results from adult daily intakes greater than 25,000 IU for 6 years or longer and more than 100,000 IU for 6 months or longer.
aster In animal cells, a star-shaped system of non-kinetochore microtubules that radiates from a centrosome or from either of the poles of the mitotic spindle during the early stages of cell division.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.